Why the study?
Cardioversion is common in AF, but whether NOACs used in clinical practice yield stroke rates similar to VKAs for cardioversion remained to be evaluated.
Do novel oral anticoagulants (NOAC) prevent stroke/TIA as effectively as vitamin K antagonists (VKA) in patients with atrial fibrillation undergoing cardioversion?
Do novel oral anticoagulants (NOAC) prevent stroke/TIA as effectively as vitamin K antagonists (VKA) in patients with atrial fibrillation undergoing cardioversion?
In real-world clinical practice, NOACs are associated with similarly low rates of stroke, death, and bleeding compared to VKAs following cardioversion for atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports comparable stroke risk with NOACs vs VKAs post-cardioversion; hypothesis-generating and should not yet change practice.
BACKGROUND: Cardioversion is common among patients with atrial fibrillation (AF). We hypothesised that novel oral anticoagulants (NOAC) used in clinical practice resulted in similar rates of stroke compared with vitamin K antagonists (VKA) for cardioversion. METHODS: Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II, patients with AF who had a cardioversion, follow-up data and an AF diagnosis within 6 months of enrolment were identified retrospectively. Clinical outcomes were compared for patients receiving a NOAC or VKA for 1 year following cardioversion. RESULTS: Among 13 004 patients with AF, 2260 (17%) underwent cardioversion. 1613 met the inclusion criteria for this analysis. At the time of cardioversion, 283 (17.5%) were receiving a VKA and 1330 (82.5%) a NOAC. A transoesophageal echocardiogram (TOE) was performed in 403 (25%) cardioversions. The incidence of stroke/transient ischaemic attack (TIA) at 30 days was the same for patients having (3.04 per 100 patient-years) or not having (3.04 per 100 patient-years) a TOE (p=0.99). There were no differences in the incidence of death (HR 1.19, 95% CI 0.62 to 2.28, p=0.61), cardiovascular hospitalisation (HR 1.02, 95% CI 0.76 to 1.35, p=0.91), stroke/TIA (HR 1.18, 95% CI 0.30 to 4.74, p=0.81) or bleeding-related hospitalisation (HR 1.29, 95% CI 0.66 to 2.52, p=0.45) at 1 year for patients treated with either a NOAC or VKA. CONCLUSIONS: Cardioversion was a low-risk procedure for patients treated with NOAC, and there were statistically similar rates of stroke/TIA 30 days after cardioversion as for patients treated with VKA. There were no statically significant differences in death, stroke/TIA or major bleeding at 1 year among patients treated with NOAC compared with VKA after cardioversion.
No takes yet. Share an insight, caveat, or question.
Geurink et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: